Screener
BridgeBio Pharma BBIO Other income, net (Note 6)
Other income, net (Note 6) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
| Total other expense, net | (60,599) | (65,236) |
| Net loss | (166,555) | (169,608) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,512 | 2,186 |
| Net loss attributable to common stockholders of BridgeBio | $(164,043) | $(167,422) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's other income, net (note 6)?
- BridgeBio Pharma (BBIO) reported other income, net (note 6) of $4.25M in Q1 2026.
- How has BridgeBio Pharma's other income, net (note 6) changed year-over-year?
- BridgeBio Pharma's other income, net (note 6) decreased by 48.3% year-over-year, from $8.23M to $4.25M.
- What is the long-term trend for BridgeBio Pharma's other income, net (note 6)?
- Over 3 years (2021 to 2025), BridgeBio Pharma's other income, net (note 6) has grown at a 6.3% compound annual growth rate (CAGR), from $35.82M to $43.06M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about BridgeBio Pharma's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude